<h2 dir="ltr"><strong>Glioblastoma Multiforme</strong></h2>
<p dir="ltr"><a href="https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market"><strong>Glioblastoma Multiforme</strong></a> is the most frequently occurring primary tumor of the central nervous system (CNS) in adults and is characterized by aggressive progression, poor prognosis, and limited long-term survival despite advances in diagnosis and treatment.</p>
<h3 dir="ltr"><strong>Glioblastoma Multiforme Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" role="presentation">Total Incident Cases of GBM</li>
<li dir="ltr" role="presentation">Gender-specific Incident Cases of GBM</li>
<li dir="ltr" role="presentation">Type-specific Incident Cases of GBM</li>
<li dir="ltr" role="presentation">Incident Cases based on Primary Site of GBM</li>
<li dir="ltr" role="presentation">Age-specific Incident Cases of GBM</li>
<li dir="ltr" role="presentation">Incident Cases based on Histologic Classification of GBM</li>
<li dir="ltr" role="presentation">Unmethylation of the MGMT Gene Promoter Cases</li>
<li dir="ltr" role="presentation">BRAF V600E Mutation Cases in GBM</li>
<li dir="ltr" role="presentation">Line-wise Treated Pool of GBM</li>
</ul>
<h2 dir="ltr"><strong>Glioblastoma Multiforme Epidemiology</strong></h2>
<ul>
<li dir="ltr" role="presentation">The total incident cases of Glioblastoma Multiforme in the 7MM were estimated at approximately 38K in 2025.</li>
<li dir="ltr" role="presentation">The United States accounted for nearly 41% of total incident cases, while EU4 and the UK represented approximately 51%, and Japan contributed nearly 8% of total incident cases in 2025.</li>
<li dir="ltr" role="presentation">According to DelveInsight&rsquo;s analysis, incident cases of GBM in the United States were estimated at approximately 15,500 in 2025 and are expected to increase during the forecast period (2026&ndash;2036) due to aging populations, increased susceptibility to oncology conditions, and growing awareness regarding early diagnosis and screening.</li>
<li dir="ltr" role="presentation">BRAF V600E mutation cases represented the largest share of incident GBM cases in the United States.</li>
<li dir="ltr" role="presentation">Age-specific incident cases in the United States were highest among patients aged 65&ndash;74 years (30%), followed by 55&ndash;64 years (27%), 75&ndash;84 years (18%), and 45&ndash;54 years (13%) in 2025.</li>
</ul>
<h2 dir="ltr"><strong>Glioblastoma Multiforme Market</strong></h2>
<ul>
<li dir="ltr" role="presentation">The Glioblastoma Multiforme market size in the 7MM was estimated at approximately USD 900 million in 2025.</li>
<li dir="ltr" role="presentation">The GBM market is expected to grow at a CAGR of 13.2% during the forecast period from 2026 to 2036.</li>
<li dir="ltr" role="presentation">Among currently available therapies, Optune &plusmn; TMZ generated the highest revenue in the United States in 2025.</li>
<li dir="ltr" role="presentation">The GBM treatment landscape continues to evolve with advancements in targeted therapies, tumor treating fields, immunotherapies, and combination treatment strategies aimed at improving survival outcomes and disease management.</li>
<li dir="ltr" role="presentation">Approved therapies including AVASTIN, TEMODAR/TEMODAL, DELYTACT, TAFINLAR/FINLEE + MEKINIST, OPTUNE GIO, and STIVARGA have expanded available treatment approaches for newly diagnosed and recurrent GBM patients.</li>
<li dir="ltr" role="presentation">Increasing investment in oncology research, expansion of innovative therapeutic modalities, and ongoing clinical development activities are expected to support future market growth across the 7MM.</li>
</ul>
<h3 dir="ltr"><strong>Glioblastoma Multiforme Market Drivers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Rising incidence of primary brain tumors is increasing the demand for effective GBM therapies.</li>
<li dir="ltr" role="presentation">Advancements in targeted therapies and immunotherapy approaches are supporting treatment innovation.</li>
<li dir="ltr" role="presentation">Increasing investment in research and development activities is accelerating clinical progress in GBM treatment.</li>
<li dir="ltr" role="presentation">Expansion of the pipeline with innovative modalities such as vaccines, tumor-targeting therapies, and cannabinoid-based approaches is driving market growth.</li>
</ul>
<h3 dir="ltr"><strong>Glioblastoma Multiforme Market Barriers</strong></h3>
<ul>
<li dir="ltr" role="presentation">The lack of curative therapies continues to limit survival outcomes in GBM patients.</li>
<li dir="ltr" role="presentation">High clinical trial failure rates and limited multicenter studies with larger patient populations remain significant development challenges.</li>
<li dir="ltr" role="presentation">Complex tumor biology and difficulties associated with successful target inhibition and drug delivery restrict treatment effectiveness.</li>
<li dir="ltr" role="presentation">Potential safety concerns and unexpected outcomes in real-world settings may impact regulatory approvals and market adoption of emerging therapies.</li>
</ul>
<h3 dir="ltr"><strong>Emerging Glioblastoma Multiforme Drugs</strong></h3>
<ul>
<li dir="ltr" role="presentation">AV-GBM-1</li>
<li dir="ltr" role="presentation">LAM561 (2-OHOA)</li>
<li dir="ltr" role="presentation">VT1021</li>
<li dir="ltr" role="presentation">TN-TC11G</li>
<li dir="ltr" role="presentation">And others</li>
</ul>
<h3 dir="ltr"><strong>Key Glioblastoma Multiforme Companies</strong></h3>
<ul>
<li dir="ltr" role="presentation">Roche (Genentech)</li>
<li dir="ltr" role="presentation">Merck</li>
<li dir="ltr" role="presentation">Daiichi Sankyo</li>
<li dir="ltr" role="presentation">Novartis</li>
<li dir="ltr" role="presentation">Novocure</li>
<li dir="ltr" role="presentation">Bayer</li>
<li dir="ltr" role="presentation">Avita Biomedical</li>
<li dir="ltr" role="presentation">TAE Life Sciences</li>
<li dir="ltr" role="presentation">Laminar Pharmaceuticals</li>
<li dir="ltr" role="presentation">Vigeo</li>
<li dir="ltr" role="presentation">Tilray</li>
<li dir="ltr" role="presentation">And others</li>
</ul>

Glioblastoma Multiforme Market

Glioblastoma Multiforme Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.